Incyte Corporation (INCY) 80.81 $INCY Covered Call

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Incyte Corporation (INCY) 80.81 $INCY

Covered Call reports for Twitter, Incyte Corp., Chico's FAS Inc., SolarCity and Bristol-Myers Squibb include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BMY, CHS, INCY, SCTY, and TWTR.
SCTY: 18.78 (-1.88), INCY: 80.81 (-0.29), BMY: 56.76 (-0.63), TWTR: 19.50 (+0.29), CHS: 12.35 (-0.33)

CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 61.42 (+1.68), INCY: 80.81 (-0.29), CTIC: 0.39 (unch), ANIK: 47.94 (+0.70)

Incyte to Present at Upcoming Investor Conferences
BusinessWire - Tue Aug 30, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
INCY: 80.81 (-0.29), MS: 31.91 (-0.15)

Forbes Magazine Names Incyte to its List of World's Most Innovative Companies for Second Consecutive Year
BusinessWire - Thu Aug 25, 6:30AM CDT
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine's 2016 list of the World's Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.
INCY: 80.81 (-0.29)

Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer
Marketwired - Thu Aug 25, 6:05AM CDT
Data Reinforces Favorable Safety Profile, Robust Immunogenicity of Company's Lead Cancer Therapy Candidate, and Highlights Optimal Dosing Schedule
IMV.TO: 0.77 (+0.02), INCY: 80.81 (-0.29)

After Yesterday's Rally of 6.97% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:25PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)

Watch for Incyte to Potentially Pullback After Gaining 6.97% Yesterday
Comtex SmarTrend(R) - Mon Aug 22, 12:23PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)

Incyte Set to Possibly Rebound After Yesterday's Selloff of 2.82%
Comtex SmarTrend(R) - Tue Aug 16, 2:54PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)

SmarTrend Watching for Potential Rebound in Shares of Incyte After 2.82% Loss
Comtex SmarTrend(R) - Tue Aug 16, 2:53PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)

Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.45 (+0.01), SYN: 1.59 (-0.05), RPTP: 7.24 (-0.21), INCY: 80.81 (-0.29)

New Strong Buy Stocks for August 10th
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 6:42AM CDT
New Strong Buy Stocks for August 10th
NGL: 18.01 (-0.13), CIM: 16.46 (-0.03), INCY: 80.81 (-0.29), GALE: 0.39 (-0.01), ACXM: 26.21 (+0.22)

Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.17 (+0.34), GERN: 2.73 (+0.04), INCY: 80.81 (-0.29), RPRX: 2.00 (-0.03)

Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
BusinessWire - Tue Aug 09, 6:00AM CDT
--ECHO-301, the first Phase 3 trial evaluating epacadostat, now underway in combination with pembrolizumab as first-line treatment of patients with advanced or metastatic melanoma
INCY: 80.81 (-0.29)

Incyte Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 08, 4:04PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)

Watch for Incyte to Potentially Rebound After Falling 2.22% Yesterday
Comtex SmarTrend(R) - Mon Aug 08, 4:02PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)

Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:05AM CDT
Will drug stocks Mylan, Incyte and Genmab be able to pull a surprise when they report Q2 results on Aug 9?
JNJ: 119.08 (-0.26), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), NVS: 78.27 (-0.50)

Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:15PM CDT
Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
IPXL: 23.94 (-0.25), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), IONS: 30.04 (+0.39)

Can TransDigm (TDG) Spring a Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:56AM CDT
TransDigm Group Incorporated (TDG) is set to report third-quarter fiscal 2016 results, after the closing bell on Aug 9.
INCY: 80.81 (-0.29), TDG: 287.41 (+2.22), MYL: 41.92 (-0.44), AGI: 7.42 (+0.40)

What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:43AM CDT
Myriad's (MYGN) earnings outpaced the Zacks Consensus Estimate in all the past four quarters, with an average beat of 8.70%.
MYGN: 20.44 (+0.08), MDT: 86.98 (-0.05), INCY: 80.81 (-0.29), IONS: 30.04 (+0.39)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading